ClinicalTrials.Veeva

Menu

Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty (ACBSL)

Lifespan logo

Lifespan

Status and phase

Enrolling
Phase 4

Conditions

Arthroplasty, Replacement, Knee
Total Knee Arthroplasty

Treatments

Drug: Lidocaine IV
Drug: Saline IV

Study type

Interventional

Funder types

Other

Identifiers

NCT04828083
1617319

Details and patient eligibility

About

The investigators are evaluating the postoperative outcomes in patients undergoing total knee arthroplasty that receive either systemic lidocaine or ultrasound-guided adductor canal block as part of their anesthetic plan.

Full description

Patients scheduled to have total knee arthroplasty will typically receive a single shot adductor canal block to serve as the primary anesthetic and as part of a multi-modal post-operative analgesic plan. The use of adductor canal block is still limited to where trained anesthesiologists in regional anesthesia are available. There are other nonopioid analgesic adjuncts, such as Lidocaine, which is is widely available and is a very commonly used local anesthetic. A major advantage of lidocaine is that it is not associated with a significant side effect profile. Intravenous lidocaine which can be administered during surgery and/or after surgery has demonstrated anti-inflammatory effects and can significantly decrease the reliance on opioid use for adequate pain management in abdominal and spine surgeries. The addition of systemic lidocaine infusion as part of a multimodal analgesia strategy to minimize opioid related side effects might prove to be a useful combination for clinicians where adductor canal blocks are not a viable option. However, the level of evidence comparing the efficacy of intravenous lidocaine versus adductor canal block to reduce postoperative opioid consumption in patients undergoing TKA is limited. We hypothesized that there will be no meaningful clinical difference between systemic lidocaine and ultrasound-guided adductor canal block in the 24-hour postoperative analgesia period.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ASA PS 1-3 patients undergoing primary, unilateral total knee arthroplasty

Exclusion criteria

  • ASA PS classification of 4 or greater
  • Pre-existing neuropathy
  • Coagulopathy
  • Chronic opioid consumption (>3 months)
  • Infection at the site
  • Known allergy to study medications (lidocaine)
  • High grade atrioventricular block (cardiac conduction system impairment)
  • A history of CVA/TIA
  • Currently using lidocaine patches
  • Known liver disease

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

120 participants in 2 patient groups

Ultrasound-guided adductor canal block with local anesthetic
Active Comparator group
Description:
Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml
Treatment:
Drug: Saline IV
Ultrasound-guided adductor canal block with saline
Sham Comparator group
Description:
Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)
Treatment:
Drug: Lidocaine IV

Trial contacts and locations

1

Loading...

Central trial contact

Vendhan Ramanujam, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems